drugset
drugset / Trial / NCT07198035

A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144

NCT07198035 ↗

Phase 1 Completed 12 enrolled Pfizer
Non-randomizedSequentialOpen-labelBasic science

Summary

The purpose of the study is to learn how the study medicine called carbamazepine changes how the body processes the other study medicine called PF-07248144. The study will also look at the safety, tolerability, and how PF-07248144 is changed and removed from the body after taking PF-07248144 alone compared to when it is taken with carbamazepine. Carbamazepine can change how your body processes some medications so it may change the body's processing of PF-07248144. Multiple blood samples will be collected up to 8 days after each dose of PF-07248144 to determine how much PF-07248144 is in the blood at different times. This will help characterize the pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it) of PF-07248144 alone and when taken with carbamazepine.

Timeline

Start
2025-09-18
Primary completion
2025-12-17
Completion
2026-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbamazepine Small molecule — Oral
Subject prifetrastat Small molecule — Oral

Indications

No indication recorded.